ADURO BIOTECH, INC. (NASDAQ:ADRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On January4, 2018,the Board of Directors (the “Board”) of Aduro Biotech, Inc. (“Aduro” or the “Company”) appointed Jennifer Lew as Aduro’s Chief Financial Officer. Ms.Lew, 45, joined Aduro in October 2013 and has served as Aduro’s Senior Vice President of Finance since January 2015. Prior to joining Aduro, from 2004 to 2013, Ms.Lew held various positions of increasing responsibility at Dynavax Technologies, culminating as Vice President of Finance and Principal Accounting Officer responsible for all accounting and finance operations. Earlier in her career Ms.Lew served as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, and was a member of the audit practice at Ernst& Young. Ms.Lew earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).
In connection with her appointment as Chief Financial Officer, the Compensation Committee of the Board approved an increased annual base salary for Ms.Lew of $385,000 with a 2018 cash bonus potential of 40% of base salary, both retroactive to January1, 2018. There are no family relationships between Ms.Lew and any director or executive officer of Aduro, and Ms.Lew has no direct or indirect material interest in any transaction required to be disclosed to Item404(a) of Regulation S-K.
Gregory W. Schafer, Aduro’s Chief Operating Officer, notified the Company on December29, 2017 that he will resign his position effective March1, 2018. In his capacity as Chief Operating Officer, Mr.Schafer had, until the appointment of Ms.Lew as Chief Financial Officer, served as the Company’s principal financial officer.
About ADURO BIOTECH, INC. (NASDAQ:ADRO)
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.